erlotinib has been researched along with dicumarol in 1 studies
Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (dicumarol) | Trials (dicumarol) | Recent Studies (post-2010) (dicumarol) |
---|---|---|---|---|---|
221 | 0 | 180 | 2,260 | 33 | 110 |
Protein | Taxonomy | erlotinib (IC50) | dicumarol (IC50) |
---|---|---|---|
Cholinesterase | Homo sapiens (human) | 0.0026 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.3 | |
NAD | Homo sapiens (human) | 0.2585 | |
Mitogen-activated protein kinase 1 | Homo sapiens (human) | 4.426 | |
Proprotein convertase subtilisin/kexin type 7 | Homo sapiens (human) | 1.3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for erlotinib and dicumarol
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |